$2.48
-0.01(-0.40%)
Mkt Cap $59M
$2.15
$11.90
52-Week Range
At A Glance
1
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers.
2
Most recently: . The information in this Item 7.01, including Exhibit 99.1 and the information on the Company’s website, shall not be deemed “filed” for purposes of Section 18 (2026-01-12).
$59M
Market Cap
—
Revenue
-$26M
Net Income
Employees10
Fundamentals
How The Business Makes Money
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001652935
ISINUS0050831009
CUSIP005083100
Phone817 887 8455
Address1751 River Run, Fort Worth, TX, 76107, US
SEC EDGAR